Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharmaron Beijing Co's Total Assets for the quarter that ended in Jun. 2026 was HK$33,483 Mil.
During the past 12 months, Pharmaron Beijing Co's average Total Assets Growth Rate was 15.00% per year.
During the past 3 years, the average Total Assets Growth Rate was 11.60% per year.
During the past 5 years, the average Total Assets Growth Rate was 22.90% per year.
During the past 10 years, the average Total Assets Growth Rate was 35.50% per year.
During the past 12 years, Pharmaron Beijing Co's highest 3-Year average Total Assets Growth Rate was 60.30%. The lowest was 11.60%. And the median was 35.30%.
Note:
The Net Income data used here is four times the quarterly (Jun. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Pharmaron Beijing Co's Asset Turnover for the quarter that ended in Jun. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Pharmaron Beijing Co Total Assets Related Terms
Pharmaron Beijing Co Total Assets Historical Data
* Premium members only.
The historical data trend for Pharmaron Beijing Co's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Pharmaron Beijing Co's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharmaron Beijing Co (HKSE:03759) has a Total Assets of HK$33,483 Mil as of Jun. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Pharmaron Beijing Co and its competitors.
Is Pharmaron Beijing Co's Total Assets too high?
Pharmaron Beijing Co's current Total Assets is HK$33,483 Mil. Overall, Pharmaron Beijing Co has a GF Score™ of 89/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pharmaron Beijing Co's Total Assets compare to VRTX and REGN?
Pharmaron Beijing Co's Total Assets of HK$33,483 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Pharmaron Beijing Co and its competitors. Pharmaron Beijing Co's current Total Assets is HK$33,483 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmaron Beijing Co stock overvalued right now?
Based on GuruFocus' analysis, Pharmaron Beijing Co (HKSE:03759) is currently considered Modestly Overvalued. The stock's GF Value™ is HK$22.55, compared to a current price of HK$28.54 — trading 26.6% above its estimated fair value. The current Total Assets is HK$33,483 Mil. Pharmaron Beijing Co's overall GF Score™ is 89/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Pharmaron Beijing Co (HKSE:03759), the current Total Assets is HK$33,483 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharmaron Beijing Co (HKSE:03759) Overvalued in 2026?
Based on GuruFocus' analysis, Pharmaron Beijing Co stock appears to be overvalued.
The current stock price of HK$28.54 is trading 26.6% above its estimated GF Value™ of HK$22.55.
GuruFocus considers Pharmaron Beijing Co to be Modestly Overvalued.
Key valuation signals for HKSE:03759:
Total Assets: HK$33,483 Mil
GF Value™: HK$22.55 vs. price of HK$28.54 (26.6% above fair value)
No single metric tells the full story. See the HKSE:03759 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal, and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry, and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. Its operating segment includes Laboratory services; CMC (small molecule CDMO) services, Clinical development services, and biologics and CGT services. It generates maximum revenue from the Laboratory services segment.
89GF Score
Get the complete analysis for HKSE:03759
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:03759 has been successfully added to your 
